DNA RNA and Cells

20 Dec 2018 Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705 for the Treatment of Non-Melanoma Skin Cancer
20 Dec 2018 Vedanta Biosciences Initiates Phase 2 Study for Lead Rationally-Defined Bacterial Consortium Product Candidate, VE303
20 Dec 2018 Exicure Announces Top-line Patient Data for Phase 1 Inflammation Program in Psoriasis
20 Dec 2018 Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective Therapy
19 Dec 2018 Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer
17 Dec 2018 Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
15 Dec 2018 NOXXON Announces Key Findings That NOX-A12 Plus Keytruda® Induces an Immune Response and Results in Clinical Benefit for Patients
14 Dec 2018 AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
14 Dec 2018 Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
14 Dec 2018 Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO
11 Dec 2018 XenoTherapeutics to Start First Human Trial of Xeno-Skin™, a Novel Xenotransplantation Treatment for Severe Burns
11 Dec 2018 Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
06 Dec 2018 iCell Gene Therapeutics Presents First-in-Human Data of CLL1-CD33 Compound CAR T in Refractory Acute Myeloid Leukemia
06 Dec 2018 Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
05 Dec 2018 Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting
04 Dec 2018 Triumvira Immunologics Demonstrates Prolonged TAC-T Cell Persistence and Efficacy in Preclinical Models
04 Dec 2018 CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018
04 Dec 2018 ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04 Dec 2018 Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
04 Dec 2018 NeoImmuneTech Presents Hyleukin-7 and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting
04 Dec 2018 Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
04 Dec 2018 Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
04 Dec 2018 WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting
04 Dec 2018 Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
04 Dec 2018 Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up